查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2096508

細胞與基因治療臨床試驗市場—2026-2032年全球市場預測

Cell & Gene Therapy Clinical Trials Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，細胞和基因療法的臨床試驗市場將成長至 259.2 億美元，複合年成長率為 12.41%。

主要市場統計數據
基準年 2025 114.3億美元
預計年份：2026年 128億美元
預測年份 2032 259.2億美元
複合年成長率 (%) 12.41%

細胞和基因療法的臨床試驗正在改變先進治療的格局，使其不再局限於症狀管理，而是能夠改變疾病進程，甚至在特定適應症中根治性。該領域涵蓋自體和異體細胞療法、病毒和非病毒基因轉移、基因編輯、基於RNA的方法以及用於腫瘤、罕見疾病、血液疾病、眼科、神經病學、免疫學和代謝性疾病的體外生產模型。隨著監管機構不斷完善關於長期追蹤、化學、生產和品管（CMK）、載體消除、等效性、療效評估和患者安全監測的指導方針，監管力度也在不斷增強。同時，臨床實驗申辦方正在應對複雜的營運要求，包括臨床實驗合格評估、專業的低溫運輸物流、白血球分離調整、個人化生產配額、分散式病患監測和高頻藥物監測。此外，臨床開發環境受到多種因素的影響，包括公開的臨床試驗註冊數據、同行評審的證據、監管指南以及醫療保健系統中精準醫療的採用（例如基因組檢測的廣泛應用、基於生物標記的患者招募以及對先進治療藥物進行系統的長期隨訪研究）。目前，最具競爭力的臨床開發策略是將嚴謹的轉化科學與擴充性的生產設計、基於真實世界數據（REW）的規劃、基於生物標記的患者選擇以及與監管機構、保險公司、臨床實驗和患者支持網路的早期合作相結合。隨著細胞和基因療法的臨床試驗擴展到不同地區和治療領域，其成功越來越取決於科學創新和可重複性、倫理管治、患者可及性和永續證據的創建之間如何取得平衡。

臨床試驗格局的變革性變化

隨著研發模式從傳統的、以研究中心為中心的藥物試驗轉向需要精確生物學表徵、精細化患者管理和數位化監測的整合治療平台，細胞和基因療法的臨床試驗格局正在經歷一場變革。試驗設計正變得更加靈活，尤其是在罕見疾病和腫瘤領域，這些領域的患者數量少、未滿足的需求迫切，且入合格標準基於生物標記，因此需要靈活的證據策略。監管機構日益重視長期安全性監測，將載體、基因組編輯技術和具有持續生物活性的產品整合到臨床試驗中，使得治療後追蹤成為方案設計的核心要素。生產也是臨床試驗中的關鍵變量，比較試驗、可追溯性管理、出庫檢測、無菌保證和療效測試都會影響受試者入組計劃和治療的一致性。同種異體細胞治療平台、體內基因治療和標靶遞送系統的擴展，也需要新的免疫療法、劑量、再治療評估和風險緩解方法。同時，臨床試驗網路正在增加對臨床實驗的專業培訓、血液分離和體液管理能力、低溫儲存、遺傳諮詢以及細胞激素釋放症候群、免疫效應細胞相關神經毒性症候群、插入突變、載體相關免疫抗原性和脫靶編輯風險等不利事件管理方案的投入。這些變化促使相關人員建構一個更具韌性、互通性和以患者為中心的研發生態系統，以支持從初始人體試驗到長期真實世界追蹤的證據產生。

人工智慧（AI）的累積影響

人工智慧 (AI) 透過改進對複雜生物學、臨床、影像學、基因組學和生產數據的解讀方式，在整個研發生命週期中對細胞和基因療法的臨床試驗產生了日益顯著的影響。在方案設計階段，AI 驅動的分析可以輔助可行性評估、最佳化納入和排除標準，並識別具有合適患者群體和營運結構的試驗中心。在受試者招募階段，機器學習模型可用於篩檢電子健康記錄、註冊資料、分子診斷結果和轉診模式，以識別潛在的合格受試者，尤其是在傳統招募管道有限的罕見疾病領域。 AI 也被應用於生物標記發現、載體設計輔助、免疫反應建模、劑量反應關係探索、數位病理學、影像分析和生產偏差預測。在試驗執行階段，先進的分析技術能夠增強遠端監測、檢測安全訊號、支援基於風險的品管，並在分散式和混合試驗模型中實現更有效率的數據審查。人工智慧實施的顯著優勢體現在資料集得到妥善管理、具備互通性並經過臨床標註，以及演算法能夠根據方案定義的結果、安全事件和生產品質屬性檢驗。然而，人工智慧的累積影響取決於透明的檢驗、偏差評估、保護隱私的資料管治、監管可追溯性、網路安全以及人工臨床監督。在細胞和基因療法的臨床試驗中，人工智慧的價值在於它能夠輔助科學決策、提高證據品質、加快操作流程並保障病人安全，而不是取代專家判斷。

全球臨床試驗生態系中的關鍵區域洞察

由於亞太地區醫院基礎設施不斷完善、患者群體大規模且遺傳多樣性高、分子診斷技術應用日益廣泛，以及在先進療法框架下與監管機構合作日益加強，該地區在細胞和基因療法臨床試驗方面的重要性日益凸顯。該地區各國正透過投資再生醫學、腫瘤學研究、罕見疾病診斷、數位醫療和生物製造能力，不斷強化其臨床試驗生態系統。其中，日本、中國、韓國、澳洲、印度和新加坡在再生醫學監管、腫瘤學研究、早期臨床試驗和轉化醫學方面都展現出獨特的優勢。歐洲擁有高度結構化的先進醫療產品環境，包括完善的監管體系、跨境研究合作、強力的倫理監督、國家健康數據舉措、移植技術專長，以及對統一醫療技術評估和長期證據積累日益成長的重視。北美仍然是細胞和基因療法早期及III期臨床試驗的主要中心，這得益於成熟的監管流程、高度專業化的大學醫學中心、經驗豐富的臨床實驗基地、先進的生產網路、基因組醫學項目以及患者權益倡導組織的積極參與。在拉丁美洲，隨著主要大都會地區臨床研究能力的提升，臨床研究的重要性日益凸顯，腫瘤學、血液學、免疫學和遺傳疾病計畫等領域的機會也隨之湧現。然而，基礎設施的差異、複雜的報銷機制、監管時間表以及溫控物流仍然是需要重點考慮的因素。非洲擁有豐富的遺傳多樣性、感染疾病的專業知識、不斷擴大的新生兒篩檢以及日益發展的臨床研究網路，因此在基因和細胞療法研究方面具有長期潛力。但是，為了實現更廣泛的參與，需要持續投資於診斷、監管能力、低溫運輸物流、人力資源發展、倫理管治以及公平的准入框架。在中東，對精準醫療、國家基因組學計劃、腫瘤中心和專業醫療保健基礎設施的投資正在取得進展，臨床試驗實施系統也在不斷成熟，一些國家正被定位為先進治療研究、區域核心醫療保健和以遺傳疾病為重點的臨床開發的新中心。

來自引領進療法發展的領先團隊的真知灼見

儘管北約成員國並非醫療衛生監管集團，但它們包含許多擁有成熟臨床研究體系、健全生物安全標準、先進醫院網路和穩健醫療基礎設施的國家，這些優勢足以支持開展複雜的臨床試驗、跨境合作、應急準備以及關鍵的生物製藥供應鏈規劃。七國集團（G7）憑藉其完善的監管體系、轉化研究能力、先進的醫院、長期安全追蹤基礎設施、罕見疾病網路以及強大的藥物安全監測系統，在高度複雜的細胞和基因治療臨床試驗中繼續發揮核心作用。金磚國家（BRICS）憑藉其多元化的患者群體、不斷增強的生物醫學能力以及對國內創新的濃厚興趣，做出了重要貢獻，其中中國、印度和巴西在規模、科研人才、臨床研究網路和生物製造發展方面發揮著尤為重要的作用。同時，監管協調、倫理標準標準化和生產一致性仍然是至關重要的因素。歐盟憑藉著集中化的科學評估、臨床試驗法規的協調統一、藥物安全監測要求、跨境研究合作以及對真實世界數據和醫療技術評估的通用重視，為先進治療藥物提供了最清晰的法規環境之一。東協正透過擴大臨床研究基礎設施、加強區域監管合作、增加對生物醫學領域的投資以及更加關注腫瘤學、罕見疾病診斷和再生醫學，來強化其在細胞和基因療法臨床試驗中的作用。儘管該地區因其人口多樣性和不斷發展的醫院網路而具有重要的戰略意義，但標準的協調統一、先進製造技術的獲取以及專業臨床實驗中心的能力仍然是關鍵優先事項。海灣合作理事會（GCC）正透過國家基因組舉措、對三級醫療的投資、數位醫療的普及以及對腫瘤學和遺傳疾病計畫日益成長的興趣，為精準醫療和先進療法做好準備，隨著監管清晰度、人才引進和永續患者獲取模式的不斷完善，為該地區參與臨床試驗創造了機會。

各國對細胞和基因治療臨床試驗的深入了解

在中國，細胞和基因治療的臨床研究正迅速發展，這得益於龐大的患者群體、對醫院的投入、監管的現代化、腫瘤學領域的專業化以及基因編輯相關科學的積極探索。然而，持續關注試驗品質、追蹤和生產等效性仍然至關重要。美國憑藉其豐富的監管經驗、專業的學術和區域癌症治療網路、罕見疾病支持體系、公共臨床試驗基礎設施以及先進的生產製造和轉化研究能力，在細胞和基因治療的臨床試驗中繼續發揮核心作用。日本擁有獨特的再生醫學框架、高品質的臨床基礎設施、系統的安全監測體係以及在監管先進醫療方面的豐富經驗。印度因其患者群體的多樣性、成本效益高的臨床運營、基因組學計劃、不斷擴大的醫院網路以及新興的生物製造能力而備受關注，儘管在專業臨床實驗中心培訓、診斷可及性和監管一致性方面仍需改進。德國憑藉其強大的生物醫學研究、醫院基礎設施、移植專業知識和生產能力，在先進療法的臨床試驗中發揮關鍵作用。英國憑藉其在先進療法監管、國家健康數據資產、基因組學計畫、適應性臨床試驗實施能力和專業臨床中心方面的專業知識，保持著強大的地位。澳洲因其高效的臨床試驗啟動流程、高品質的醫療保健系統、早期研究能力以及與國際良好臨床實踐（GCP）標準的高度契合而備受讚譽。法國透過其大學醫院網路、罕見疾病基礎設施、細胞療法專業知識和強力的法律規範，支持細胞和基因療法的發展。韓國正透過對生物製造、醫院創新、數位健康基礎設施的投資以及對先進生物製藥的強力政策支持而迅速發展。義大利和西班牙擁有經驗豐富的臨床試驗基地、移植專業知識、腫瘤網路、罕見疾病計畫以及充滿活力的整體療法學術研究環境。加拿大透過其強大的大學醫院、臨床試驗品質標準、基因組學計劃和不斷擴展的生物製造項目，支持先進療法的研究。俄羅斯擁有強大的科學研究能力和龐大的病患群體，但其參與國際臨床試驗受到地緣政治因素、法規、供應鏈和營運限制的限制。巴西擁有完善的三級醫療設施、腫瘤學和血液學方面的專長，並且對細胞療法的興趣日益濃厚，是拉丁美洲臨床研究的重要貢獻者；然而，在運營安排和准入途徑方面需要周密的規劃。墨西哥正在擴大其在臨床研究領域的參與度，尤其是在大都會圈醫療體系內，但持續進展將取決於專業設施的準備情況、監管的可預測性、轉診途徑以及完善的物流。

為行業領導者提供的實用建議

行業領導者應優先考慮從臨床試驗早期階段就制定整合的臨床開發策略，協調科學證據、生產可行性、監管要求和患者獲取計劃。方案設計應圍繞檢驗的生物標記、明確的終點、完善的安全監測以及長期追蹤框架展開，以評估藥物的持久性、延遲不利事件、免疫反應、載體相關風險和真實世界療效。申辦者和研究網路應投資於具備成熟能力的合格臨床實驗中心，這些中心應具備血球分離、細胞處理、輸注、低溫儲存、遺傳諮詢、緊急應變和方案特定培訓等方面的能力。生產策略應被視為核心臨床風險領域，確保嚴格的身份鍊和監管鏈控制、放行試驗準備、可比性規劃、污染預防、檢驗的運輸路線以及緊急應變能力。只有在有效性、可審計性、資料隱私、網路安全和監管批准得到明確保障的情況下，才應選擇性地實施數位化工具和人工智慧驅動的分析。應透過登記系統、基因檢測夥伴關係、針對轉診機構的宣傳活動、酌情與新生兒篩檢協調、與患者權益倡導團體合作以及提供符合文化背景的知情同意書等方式加強患者招募。領導者還應制定區域分散化策略，在確保合格的患者能夠獲得治療的同時，兼顧監管成熟度、設施品質、後勤保障、倫理監督以及長期追蹤的可行性。最後，與保險公司和醫療保健系統儘早開展合作至關重要，以便使臨床證據的產生與未來的准入需求保持一致，尤其對於那些早期階段高度複雜且聲稱具有長期價值的療法而言更是如此。

調查方法

評估細胞和基因療法臨床試驗的調查方法應結合一手和二手研究、監管資訊、臨床試驗註冊庫分析、同行評審文獻綜述以及專家檢驗。一手研究應包括對臨床研究人員、監管專家、生產管理人員、臨床試驗營運專家、倫理委員會成員、病患權益組織代表和醫療政策制定者的訪談。二手研究應參考官方監管指南、公開的臨床試驗資料庫、科學期刊、會議論文集、公共衛生出版刊物、治療指南、藥物警戒資源以及國際良好臨床實踐（GCP）標準。應採用數據三角測量法來檢視不同治療領域、治療方法、地區、試驗階段、運作模式、病患族群和安全性方面的趨勢。調查方法應檢驗方案設計、終點選擇、病患合格、受試者招募趨勢、研究中心能力、生產依賴性、物流、長期檢驗要求、數位化技術應用以及真實世界資料（REW）規劃。品管必須包括檢驗資訊來源、檢查一致性、進行專家評審以及排除不實的說法、市場規模、市場佔有率和預測假設。由於該領域發展迅速，因此必須持續監測監管動態、臨床試驗暫停、安全通告、新的指導文件、臨床試驗變更以及試驗設計創新，以確保分析的準確性。

結論

細胞和基因療法的臨床試驗已進入一個更成熟的階段，其特點是科學嚴謹性、操作複雜性、監管審查以及全球擴張。未來的進展取決於能否在確保病人安全、生產一致性、倫理透明度和公平取得的同時，產生永續的臨床證據。擁有健全的管理體制、先進的臨床基礎設施、專家人才、可靠的診斷技術和整合資料處理能力的地區和國家，最有利於支援高品質的研發。人工智慧、分散式監測、分子診斷和真實世界數據將繼續影響試驗效率，但它們的價值在於檢驗、管治和臨床相關性。對於產業領導者而言，策略重點不再只是加快臨床試驗的啟動速度，而是建立一個能夠滿足個人化醫療、複雜生物學、長期追蹤和不斷變化的獲取途徑等需求的韌性生態系統。兼具創新性和執行力的機構，最有能力將細胞和基因療法的臨床試驗從實驗階段推進到真正造福患者的治療階段。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：細胞和基因療法的臨床試驗市場：依療法類型分類

  • 細胞療法
  • 基因治療
  • 組織工程產品

第8章：細胞和基因療法的臨床試驗市場：按給藥方法分類

  • 非病毒載體
    • 電穿孔
    • 脂質奈米顆粒
  • 病毒載體
    • 腺結合病毒
    • 腺病毒
    • 逆轉錄病毒

第9章：細胞與基因治療臨床試驗市場：依臨床試驗階段分類

  • 第一階段
  • 第二階段
  • 第三階段

第10章：細胞與基因療法臨床試驗市場：依治療來源分類

  • 自體療法
  • 順勢療法

第11章：細胞與基因治療臨床試驗市場：依生產類型分類

  • 內部生產
  • 外包委託製造

第12章：細胞與基因治療臨床試驗市場：依最終使用者分類

  • 製藥公司
  • 生技公司
  • 學術研究機構
  • 受託研究機構
  • 政府機構和非營利組織

第13章：細胞與基因治療臨床試驗市場：按地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第14章：細胞與基因治療臨床試驗市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第15章：細胞與基因治療臨床試驗市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Advanced Clinical LLC
  • Allucent Holdings, Inc.
  • Almac Group Limited
  • BioAgilytix Labs, LLC
  • BioCentriq LLC
  • Caidya Group, Inc.
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • ClinChoice Inc.
  • CTI Clinical Trial and Consulting Services, Inc.
  • Frontage Laboratories, Inc.
  • ICON plc
  • IQVIA Holdings Inc.
  • KCR SA
  • Labcorp Holdings Inc.
  • Lonza Group AG
  • Medpace Holdings, Inc.
  • Miltenyi Biotec BV & Co. KG
  • Novotech Health Holdings Pte. Ltd.
  • Parexel International Corporation
  • Pharmaron Beijing Co., Ltd.
  • PPD, Inc.
  • Precision for Medicine, Inc.
  • Samsung Biologics Co., Ltd.
  • Syneos Health, Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Veristat, LLC
  • Worldwide Clinical Trials Holdings, Inc.
  • WuXi AppTec Co., Ltd.
Product Code: MRR-0D217D5AEB5A

The Cell & Gene Therapy Clinical Trials Market is projected to grow by USD 25.92 billion at a CAGR of 12.41% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.43 billion
Estimated Year [2026] USD 12.80 billion
Forecast Year [2032] USD 25.92 billion
CAGR (%) 12.41%

Cell and gene therapy clinical trials are reshaping advanced therapeutics by moving beyond symptom management toward potentially disease-modifying and, in select indications, curative interventions. The field spans autologous and allogeneic cell therapies, viral and non-viral gene delivery, gene editing, RNA-enabled approaches, and ex vivo manufacturing models for oncology, rare diseases, hematology, ophthalmology, neurology, immunology, and metabolic disorders. Regulatory momentum has strengthened as agencies refine guidance on long-term follow-up, chemistry, manufacturing, and controls, vector shedding, comparability, potency assays, and patient safety monitoring. At the same time, trial sponsors are navigating complex operational demands, including site qualification, specialized cold chain logistics, leukapheresis coordination, individualized manufacturing slots, decentralized patient monitoring, and high-intensity pharmacovigilance. The clinical development environment is also shaped by verified trends across public trial registries, peer-reviewed evidence, regulatory guidance, and health-system adoption of precision medicine, including growing use of genomic testing, biomarker-led enrollment, and structured long-term follow-up for advanced therapy medicinal products. The most competitive clinical development strategies now combine rigorous translational science with scalable manufacturing design, real-world evidence planning, biomarker-led patient selection, and early engagement with regulators, payers, investigators, and patient advocacy networks. As cell and gene therapy clinical trials expand across regions and therapeutic areas, success increasingly depends on balancing scientific innovation with reproducibility, ethical governance, patient access, and durable evidence generation.

Transformative Shifts in the Clinical Trial Landscape

The cell and gene therapy clinical trial landscape is undergoing transformative change as development models shift from conventional, site-centric drug trials toward integrated therapeutic platforms requiring precise biological characterization, high-touch patient management, and digitally enabled oversight. Trial design is becoming more adaptive, particularly in rare diseases and oncology where small patient populations, urgent unmet needs, and biomarker-defined eligibility demand flexible evidence strategies. Regulators have increasingly emphasized long-term safety surveillance for integrating vectors, genome editing technologies, and products with durable biological activity, making post-treatment follow-up a central component of protocol architecture. Manufacturing has also become a defining clinical variable, with comparability studies, chain-of-identity controls, release testing, sterility assurance, and potency assays influencing enrollment timelines and treatment consistency. The expansion of allogeneic cell therapy platforms, in vivo gene therapies, and targeted delivery systems is prompting new approaches to immune management, dosing, retreatment evaluation, and risk mitigation. In parallel, clinical trial networks are investing in specialized investigator training, apheresis and infusion capabilities, cryogenic storage, genetic counseling, and adverse event management protocols for cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, insertional mutagenesis, vector-related immunogenicity, and off-target editing risk. These shifts are pushing stakeholders to build more resilient, interoperable, and patient-centered development ecosystems capable of supporting evidence generation from first-in-human studies through long-term real-world follow-up.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing cell and gene therapy clinical trials by improving how complex biological, clinical, imaging, genomic, and manufacturing data are interpreted across the development lifecycle. In protocol design, AI-enabled analytics can support feasibility assessment, inclusion and exclusion criteria optimization, and identification of trial sites with relevant patient populations and operational readiness. In patient recruitment, machine learning models can help screen electronic health records, registry data, molecular diagnostic results, and referral patterns to identify potentially eligible participants, especially in rare diseases where traditional recruitment pathways are limited. AI is also being applied to biomarker discovery, vector design support, immune response modeling, dose-response exploration, digital pathology, imaging analysis, and prediction of manufacturing deviations. During trial execution, advanced analytics can enhance remote monitoring, detect safety signals, support risk-based quality management, and streamline data review across decentralized or hybrid study models. Verified implementation remains strongest where datasets are curated, interoperable, and clinically annotated, and where algorithms can be tested against protocol-defined outcomes, safety events, and manufacturing quality attributes. However, the cumulative impact of AI depends on transparent validation, bias assessment, privacy-preserving data governance, regulatory traceability, cybersecurity, and human clinical oversight. For cell and gene therapy trials, AI is most valuable when it augments scientific decision-making, strengthens evidence quality, accelerates operational workflows, and supports patient safety without replacing expert judgment.

Key Regional Insights Across Global Trial Ecosystems

Asia-Pacific is becoming increasingly important for cell and gene therapy clinical trials due to its expanding hospital infrastructure, large genetically diverse patient populations, rising use of molecular diagnostics, and growing regulatory engagement across advanced therapy frameworks. Countries in the region are strengthening clinical trial ecosystems through investments in regenerative medicine, oncology research, rare disease diagnostics, digital health, and biomanufacturing capacity, with Japan, China, South Korea, Australia, India, and Singapore contributing distinctive capabilities in regenerative medicine regulation, oncology studies, early-phase trials, and translational science. Europe offers a highly structured advanced therapy medicinal product environment, with established regulatory science, cross-border research collaboration, strong ethics oversight, national health data initiatives, transplantation expertise, and growing emphasis on harmonized health technology assessment and long-term evidence generation. North America remains a leading hub for early-stage and pivotal cell and gene therapy trials, supported by mature regulatory pathways, specialized academic medical centers, experienced trial sites, advanced manufacturing networks, genomic medicine programs, and strong patient advocacy participation. Latin America is gaining relevance as clinical research capabilities expand in major urban centers, with opportunities linked to oncology, hematology, immunology, and inherited disease programs, although infrastructure variability, reimbursement complexity, regulatory timelines, and temperature-controlled logistics remain important considerations. Africa presents long-term potential for gene therapy and cell therapy research through its genetic diversity, infectious disease expertise, newborn screening expansion, and growing clinical research networks, but broader participation requires sustained investment in diagnostics, regulatory capacity, cold chain logistics, workforce training, ethics governance, and equitable access frameworks. The Middle East is investing in precision medicine, national genomics programs, oncology centers, and specialized healthcare infrastructure, positioning selected countries as emerging destinations for advanced therapy research, regional referral care, and inherited disease-focused clinical development where trial readiness continues to mature.

Key Group Insights Shaping Advanced Therapy Development

NATO member countries, while not a healthcare regulatory bloc, include many nations with mature clinical research systems, robust biosecurity standards, advanced hospital networks, and resilient medical infrastructure that support complex trial execution, cross-border collaboration, emergency preparedness, and critical biopharmaceutical supply chain planning. G7 countries continue to anchor high-complexity cell and gene therapy trials through established regulatory systems, translational research capacity, advanced hospitals, long-term safety follow-up infrastructure, rare disease networks, and strong pharmacovigilance systems. BRICS countries contribute substantial patient diversity, expanding biomedical capabilities, and strong interest in domestic innovation, with China, India, and Brazil particularly relevant for scale, scientific talent, clinical research networks, and biomanufacturing development, while regulatory alignment, ethics standardization, and manufacturing consistency remain decisive. The European Union provides one of the most defined regulatory environments for advanced therapy medicinal products, supported by centralized scientific assessment, clinical trial regulation harmonization, pharmacovigilance requirements, cross-border research collaboration, and shared priorities around real-world evidence and health technology assessment. ASEAN is strengthening its role in cell and gene therapy clinical trials through expanding clinical research infrastructure, regional regulatory cooperation, growing biomedical investment, and increasing focus on oncology, rare disease diagnosis, and regenerative medicine. The region's diverse populations and improving hospital networks make it strategically relevant, although harmonized standards, advanced manufacturing access, and specialized site capabilities remain critical priorities. The GCC is advancing precision medicine and advanced therapy readiness through national genomics initiatives, tertiary care investment, digital health adoption, and growing interest in oncology and inherited disease programs, creating opportunities for regional clinical trial participation where regulatory clarity, specialized workforce capacity, and sustainable patient access models continue to mature.

Key Country Insights for Cell and Gene Therapy Trials

China has rapidly expanded cell and gene therapy clinical research, driven by large patient access, hospital investment, regulatory modernization, oncology specialization, and strong activity in gene editing-related science, while continued attention to trial quality, follow-up, and manufacturing comparability remains essential. The United States remains central to cell and gene therapy clinical trials due to its extensive regulatory experience, specialized academic and community oncology networks, rare disease advocacy ecosystem, public clinical trial infrastructure, and concentration of advanced manufacturing and translational research capabilities. Japan offers a distinctive regenerative medicine framework, high-quality clinical infrastructure, structured safety oversight, and strong experience in advanced therapy regulation. India is gaining attention due to its patient diversity, cost-efficient clinical operations, genomics initiatives, expanding hospital networks, and emerging biomanufacturing capabilities, with continued need for specialized site training, diagnostic access, and regulatory consistency. Germany combines robust biomedical research, hospital infrastructure, transplantation expertise, and manufacturing capabilities, making it highly relevant for advanced therapy trials. The United Kingdom maintains a strong position through advanced therapy regulatory expertise, national health data assets, genomics programs, adaptive trial capabilities, and specialist clinical centers. Australia is valued for efficient clinical trial start-up pathways, high-quality healthcare systems, early-phase research capabilities, and strong alignment with international good clinical practice standards. France supports cell and gene therapy development through academic medical networks, rare disease infrastructure, cell therapy expertise, and strong regulatory oversight. South Korea is advancing rapidly through biomanufacturing investment, hospital-based innovation, digital health infrastructure, and strong policy support for advanced biotherapeutics. Italy and Spain contribute experienced clinical sites, transplantation expertise, oncology networks, rare disease programs, and active academic research environments across advanced therapies. Canada supports advanced therapy research through strong academic hospitals, clinical trial quality standards, genomics initiatives, and growing biomanufacturing programs. Russia has scientific capabilities and patient population depth, but international trial participation is shaped by geopolitical, regulatory, supply chain, and operational constraints. Brazil is a major Latin American clinical research contributor with established tertiary centers, oncology expertise, hematology capabilities, and increasing interest in cell therapy, although operational timelines and access pathways require careful planning. Mexico is expanding clinical research participation, particularly in large metropolitan healthcare systems, while continued progress depends on specialized site readiness, regulatory predictability, referral pathways, and advanced logistics.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize integrated clinical development strategies that align scientific rationale, manufacturing feasibility, regulatory expectations, and patient access planning from the earliest trial stages. Protocols should be designed around validated biomarkers, clearly defined endpoints, robust safety monitoring, and long-term follow-up frameworks that address durability, delayed adverse events, immune responses, vector-related risks, and real-world outcomes. Sponsors and research networks should invest in qualified sites with proven capabilities in apheresis, cell handling, infusion, cryogenic storage, genetic counseling, emergency management, and protocol-specific training. Manufacturing strategy should be treated as a core clinical risk area, with strong chain-of-identity and chain-of-custody controls, release testing readiness, comparability planning, contamination prevention, validated shipping lanes, and contingency capacity. Digital tools and AI-enabled analytics should be adopted selectively where validation, auditability, data privacy, cybersecurity, and regulatory acceptance are clear. Patient recruitment should be strengthened through registries, genetic testing partnerships, referral education, newborn screening linkages where appropriate, advocacy engagement, and culturally appropriate informed consent materials. Leaders should also build regional diversification strategies that balance access to eligible patients with regulatory maturity, site quality, logistics, ethics oversight, and long-term follow-up feasibility. Finally, early payer and health system engagement is essential to align clinical evidence generation with future access requirements, particularly for therapies with high upfront complexity and long-term value claims.

Research Methodology

The research methodology for evaluating cell and gene therapy clinical trials should combine primary and secondary research, regulatory intelligence, clinical trial registry analysis, peer-reviewed literature review, and expert validation. Primary inputs should include interviews with clinical investigators, regulatory specialists, manufacturing leaders, trial operations professionals, ethics committee members, patient advocacy representatives, and healthcare decision-makers. Secondary research should draw from official regulatory guidance, public clinical trial databases, scientific journals, conference proceedings, public health agency publications, treatment guidelines, pharmacovigilance resources, and international good clinical practice standards. Data triangulation should be used to validate trends across therapeutic areas, modalities, geographies, trial phases, operational models, patient populations, and safety considerations. The methodology should examine protocol design, endpoint selection, patient eligibility, recruitment dynamics, site capabilities, manufacturing dependencies, logistics, long-term follow-up requirements, digital technology adoption, and real-world evidence planning. Quality control should include source verification, consistency checks, expert review, and exclusion of unsupported claims, market sizing, market share, and forecasting assumptions. Because the field is evolving rapidly, continuous monitoring of regulatory updates, clinical holds, safety communications, new guidance documents, clinical trial amendments, and trial design innovations is essential for maintaining analytical accuracy.

Conclusion

Cell and gene therapy clinical trials are entering a more mature phase defined by scientific precision, operational complexity, regulatory scrutiny, and global expansion. The next stage of progress will depend on the ability to generate durable clinical evidence while ensuring patient safety, manufacturing consistency, ethical transparency, and equitable access. Regions and countries with strong regulatory systems, advanced clinical infrastructure, specialized workforce capacity, reliable diagnostics, and integrated data capabilities are best positioned to support high-quality development. Artificial intelligence, decentralized monitoring, molecular diagnostics, and real-world evidence will continue to influence trial efficiency, but their value will depend on validation, governance, and clinical relevance. For industry leaders, the strategic priority is no longer simply initiating trials faster; it is building resilient ecosystems that can manage individualized therapies, complex biology, long-term follow-up, and evolving access expectations. Organizations that align innovation with execution discipline will be better prepared to advance cell and gene therapy clinical trials from experimental promise to meaningful patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cell & Gene Therapy Clinical Trials Market, by Therapy Type

  • 7.1. Introduction
  • 7.2. Cell Therapy
  • 7.3. Gene Therapy
  • 7.4. Tissue Engineered Products

8. Cell & Gene Therapy Clinical Trials Market, by Delivery Method

  • 8.1. Introduction
  • 8.2. Non-Viral Vector
    • 8.2.1. Electroporation
    • 8.2.2. Lipid Nanoparticle
  • 8.3. Viral Vector
    • 8.3.1. Adeno-Associated Virus
    • 8.3.2. Adenoviral
    • 8.3.3. Retroviral

9. Cell & Gene Therapy Clinical Trials Market, by Trial Phase

  • 9.1. Introduction
  • 9.2. Phase I
  • 9.3. Phase II
  • 9.4. Phase III

10. Cell & Gene Therapy Clinical Trials Market, by Therapy Source

  • 10.1. Introduction
  • 10.2. Autologous Therapies
  • 10.3. Allogeneic Therapies

11. Cell & Gene Therapy Clinical Trials Market, by Manufacturing Type

  • 11.1. Introduction
  • 11.2. In-House Manufacturing
  • 11.3. Outsourced Manufacturing

12. Cell & Gene Therapy Clinical Trials Market, by End User

  • 12.1. Introduction
  • 12.2. Pharmaceutical Companies
  • 12.3. Biotechnology Companies
  • 12.4. Academic & Research Institutes
  • 12.5. Contract Research Organizations
  • 12.6. Government & Non-profit Organizations

13. Cell & Gene Therapy Clinical Trials Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. Europe
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Africa
  • 13.6. Middle East

14. Cell & Gene Therapy Clinical Trials Market, by Group

  • 14.1. NATO
  • 14.2. G7
  • 14.3. BRICS
  • 14.4. European Union
  • 14.5. ASEAN
  • 14.6. GCC

15. Cell & Gene Therapy Clinical Trials Market, by Country

  • 15.1. China
  • 15.2. United States
  • 15.3. Japan
  • 15.4. India
  • 15.5. Germany
  • 15.6. United Kingdom
  • 15.7. Australia
  • 15.8. France
  • 15.9. South Korea
  • 15.10. Italy
  • 15.11. Canada
  • 15.12. Russia
  • 15.13. Brazil
  • 15.14. Mexico
  • 15.15. Spain

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Advanced Clinical LLC
  • 17.2. Allucent Holdings, Inc.
  • 17.3. Almac Group Limited
  • 17.4. BioAgilytix Labs, LLC
  • 17.5. BioCentriq LLC
  • 17.6. Caidya Group, Inc.
  • 17.7. Catalent, Inc.
  • 17.8. Charles River Laboratories International, Inc.
  • 17.9. ClinChoice Inc.
  • 17.10. CTI Clinical Trial and Consulting Services, Inc.
  • 17.11. Frontage Laboratories, Inc.
  • 17.12. ICON plc
  • 17.13. IQVIA Holdings Inc.
  • 17.14. KCR S.A.
  • 17.15. Labcorp Holdings Inc.
  • 17.16. Lonza Group AG
  • 17.17. Medpace Holdings, Inc.
  • 17.18. Miltenyi Biotec B.V. & Co. KG
  • 17.19. Novotech Health Holdings Pte. Ltd.
  • 17.20. Parexel International Corporation
  • 17.21. Pharmaron Beijing Co., Ltd.
  • 17.22. PPD, Inc.
  • 17.23. Precision for Medicine, Inc.
  • 17.24. Samsung Biologics Co., Ltd.
  • 17.25. Syneos Health, Inc.
  • 17.26. Takara Bio Inc.
  • 17.27. Thermo Fisher Scientific Inc.
  • 17.28. Veristat, LLC
  • 17.29. Worldwide Clinical Trials Holdings, Inc.
  • 17.30. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TISSUE ENGINEERED PRODUCTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TISSUE ENGINEERED PRODUCTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TISSUE ENGINEERED PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NON-VIRAL VECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NON-VIRAL VECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NON-VIRAL VECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ELECTROPORATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ELECTROPORATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ELECTROPORATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LIPID NANOPARTICLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LIPID NANOPARTICLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LIPID NANOPARTICLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VIRAL VECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VIRAL VECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VIRAL VECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ADENO-ASSOCIATED VIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ADENO-ASSOCIATED VIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ADENO-ASSOCIATED VIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ADENOVIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ADENOVIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ADENOVIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RETROVIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RETROVIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RETROVIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PHASE I MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PHASE II MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PHASE III MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AUTOLOGOUS THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AUTOLOGOUS THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AUTOLOGOUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ALLOGENEIC THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ALLOGENEIC THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ALLOGENEIC THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IN-HOUSE MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IN-HOUSE MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IN-HOUSE MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OUTSOURCED MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OUTSOURCED MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OUTSOURCED MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GOVERNMENT & NON-PROFIT ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GOVERNMENT & NON-PROFIT ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GOVERNMENT & NON-PROFIT ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. NATO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. NATO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. NATO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 134. NATO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 135. NATO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 136. NATO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 137. NATO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 138. NATO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. NATO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. G7 CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. G7 CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. G7 CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 143. G7 CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 144. G7 CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 145. G7 CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 146. G7 CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 147. G7 CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. G7 CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. GCC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GCC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. GCC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 179. GCC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 180. GCC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 181. GCC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 182. GCC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 183. GCC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. GCC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. JAPAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. JAPAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. JAPAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 207. JAPAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 208. JAPAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 209. JAPAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 210. JAPAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 211. JAPAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. JAPAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. INDIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. INDIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. INDIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 216. INDIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 217. INDIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 218. INDIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 219. INDIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 220. INDIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. INDIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 225. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 226. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 227. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 228. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 229. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. AUSTRALIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. AUSTRALIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. AUSTRALIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 243. AUSTRALIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 244. AUSTRALIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 245. AUSTRALIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 246. AUSTRALIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 247. AUSTRALIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. AUSTRALIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 252. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 253. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 254. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 255. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 256. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. SOUTH KOREA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 259. SOUTH KOREA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. SOUTH KOREA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 261. SOUTH KOREA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 262. SOUTH KOREA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 263. SOUTH KOREA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 264. SOUTH KOREA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 265. SOUTH KOREA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. SOUTH KOREA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 270. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 271. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 272. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 273. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 274. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 277. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 279. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 280. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 281. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 282. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 283. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 286. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 288. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 289. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 290. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 291. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 292. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 295. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 297. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 298. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 299. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 300. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 301. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 303. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 304. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 306. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 307. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 308. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 309. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 310. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 312. SPAIN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 313. SPAIN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. SPAIN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 315. SPAIN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 316. SPAIN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECT